Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Partow Kebriaei et al.|The Lancet Oncology|2012Cited by 411
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosisPaul M. Derderian, Michael Keating, H. Kantarjian et al.|The American Journal of Medicine|1993Cited by 111